Notwithstanding promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial opposition from pharmacy benefit managers. Such https://woodyorxk182909.dm-blog.com/42371364/the-medication-faces-is-encountering-pbm-hurdles-the-look-at-access-fights